Get the Stockscreener App
127.87
3.78%
5.00
Insmed Inc stock is traded at $127.87, with a volume of 4.00M.
It is up +3.78% in the last 24 hours and up +25.14% over the past month.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
See More
Previous Close:
$122.87
Open:
$125.5
24h Volume:
4.00M
Relative Volume:
1.08
Market Cap:
$27.01B
Revenue:
$381.03M
Net Income/Loss:
$-1.01B
P/E Ratio:
-21.49
EPS:
-5.95
Net Cash Flow:
$-789.25M
1W Performance:
+16.66%
1M Performance:
+25.14%
6M Performance:
+60.77%
1Y Performance:
+70.31%
1-Day Range:
$123.50
$128.48
1-Week Range:
$107.07
$128.48
52-Week Range:
$60.40
$128.48
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
127.78 | 25.79B | 381.03M | -1.01B | -789.25M | -5.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.00 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
566.35 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.72 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.80 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.38 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Pulmonary Hypertension associated with Interstitial Lung Disease Market to Witness Upsurge in Growth During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Truist Securities raises Insmed stock price target to $139 on brensocatib pricing - Investing.com Canada
Insmed stock price target raised to $240 from $120 at H.C. Wainwright - Investing.com Canada
Insmed stock price target raised to $145 from $121 at Stifel on Brinsupri approval - Investing.com Canada
Insmed Incorporated shares rise 3.37% premarket after multiple price target adjustments from UBS, RBC Capital, Mizuho, and Morgan Stanley. - AInvest
Insmed Incorporated May Be Forming Higher Low — Chartwatchers AlertJuly 2025 Breakouts & Real-Time Buy Signal Notifications - 선데이타임즈
Insmed Rises 0.71% as Volume Ranks 224th Post-FDA Approval Price Target Hiked to 240 - AInvest
Insmed Announces FDA Approval For Drug To Treat Chronic Lung Disease - MSN
Insmed: HC Wainwright Raises PT to $240 from $120, Maintains Buy Rating - AInvest
Insmed and VytlOne: A Groundbreaking Partnership in Rare Disease Innovation - AInvest
VytlOne Announces New Partnership with Insmed - Yahoo Finance
Insmed stock downgraded at Morgan Stanley (INSM:NASDAQ) - Seeking Alpha
Insmed stock price target raised to $154 from $135 at TD Cowen on Brinsupri approval - Investing.com Canada
Goldman Sachs Raises Insmed Buy Rating to $142, PT from $114 - AInvest
Insmed stock price target raised to $138 from $120 at RBC Capital - Investing.com Canada
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week - Stocktwits
UBS Adjusts Insmed Price Target to $140 From $133, Maintains Buy Rating - MarketScreener
PANTHERx Rare Selected by Insmed to Dispense BRINSUPRI (Brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis - 富途牛牛
Insmed wins FDA approval for future blockbuster Brinsupri - Yahoo Finance
Mizuho raises Insmed stock price target to $165 following Brinsupri approval - Investing.com Canada
Morgan Stanley Downgrades Insmed to Equal Weight From Overweight, Adjusts Price Target to $126 From $112 - MarketScreener
Mizuho Adjusts Price Target on Insmed to $165 From $130, Maintains Outperform Rating - MarketScreener
Mizuho Raises Price Target for Insmed (INSM) to $165 | INSM Stoc - GuruFocus
Insmed secures FDA approval for Brinsupri to treat NCFB - World Pharmaceutical Frontiers
Insmed stock price target raised to $140 from $130 at Wells Fargo - Investing.com Canada
Jefferies Raises Price Target on Insmed (INSM) to $148 | INSM Stock News - GuruFocus
Insmed gets first FDA approval for bronchiectasis - pharmaphorum
Insmed stock rating downgraded to Equalweight by Morgan Stanley - Investing.com Canada
Insmed (INSM) Receives Positive Analyst Ratings and Price Target Increases - AInvest
Insmed Price Target Raised to $140, Wells Fargo Keeps Overweight Rating. - AInvest
Wells Fargo Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $140 - 富途牛牛
Insmed (INSM) Surges 8.07% as Bullish Candlesticks and MACD Golden Cross Signal 65% Outperformance Probability - AInvest
Insmed Surges 8.07% on FDA Approval as $870M Trading Volume Hits Top 500 Daily Rank - AInvest
US FDA approves Insmed's drug as first treatment for a chronic lung disease - Reuters
Wells Fargo Raises Price Target for INSM to $140, Maintains Over - GuruFocus
Insmed: Wells Fargo Reiterates Overweight, Raises PT to $140 from $130 - AInvest
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease - AOL.com
FDA Approves Insmed’s Brensocatib as First Therapy for Non-Cystic Fibrosis Bronchiectasis - geneonline.com
Insmed gains US approval of lung disease drug forecast to be blockbuster - BioPharma Dive
Brinsupri dose choice means bronchiectasis upside, Insmed says - BioWorld MedTech
Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval - Investor's Business Daily
BofA Securities Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $121 - 富途牛牛
Jefferies raises Insmed stock price target to $148 on Brinsupri approval - Investing.com Canada
Insmed Rises on Drug Approval for Debilitating Lung Disease - Bloomberg.com
Insmed scores FDA clearance for Brinsupri in NCFB - BioWorld MedTech
FDA Approves Insmed's Brinsupri for Chronic Lung Disease Treatment - AInvest
US FDA approves Insmed’s drug as first treatment for a chronic lung disease - The Mighty 790 KFGO
Insmed gets FDA approval for the first DPP1 inhibitor, in lung disease - Endpoints News
Insmed's Brinsupri: A Blockbuster Launch in a Neglected Market - AInvest
Insmed Surges 4.6% on FDA Approval Breakthrough—Can This Momentum Sustain? - AInvest
Insmed stock rises on FDA nod for lung disorder drug Brinsupri - Seeking Alpha
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.02%
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):